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Understanding and controlling an MRSA
outbreak using whole genome sequencing
S. Harris
Wellcome Trust Sanger Institute, Cambridge, United
Kingdom
The emergence of meticillin-resistant Staphylococcus aureus
(MRSA) that can persist in the community and replace existing
hospital-adapted lineages of MRSA means that it is necessary to
understand transmission dynamics within and between hospitals
and the community.WestudiedaputativeMRSAoutbreakona spe-
cial care baby unit (SCBU) at Addenbrooke’s Hospital, Cambridge,
UK. We used whole-genome sequencing to assess and improve-
upon the ﬁndings of an infection-control team who evaluated the
outbreak with conventional epidemiological analysis and antibi-
ogram proﬁles. We sequenced isolates from all colonised infants
on the SCBU, and from patients in the hospital or community who
had presented with MRSA with the same antibiotic susceptibility
proﬁle as the outbreak strain. The original infection control team
identiﬁed 12 cases of MRSA infection in infants over a 12-month
periodwhichwere suspected of being linked.However, a persistant
outbreak could not be conﬁrmed. Usingwhole-genome sequencing
we identiﬁed 26 related cases of MRSA carriage and showed trans-
mission occurredwithin the SCBU, betweenmothers on a postnatal
ward, and in the community. Basedonour results,wealsoproposed
that MRSA carriage by a staff member had allowed the outbreak to
persist during a period without known infection on the SCBU and
after a deep clean. Staff screening led to identiﬁcation anddecoloni-
sation of a staff carrier, which brought the outbreak on the ward to
a close. Whole-genome sequencing holds great promise for rapid,
accurate, and comprehensive identiﬁcation of bacterial transmis-
sion pathways both within hospitals and in the community, and
its widespread use in the clinical setting will bring reductions in
infections, morbidity, and costs.
http://dx.doi.org/10.1016/j.ijid.2014.03.493
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The role of the patient and family in infection
prevention
A. Duse
National Health Laboratory Service, Johannesburg,
South Africa
Infectious diseases remain a signiﬁcant cause of morbidity and
mortality worldwide accounting for more than 13 million deaths
annually. Infection prevention and control (IPC) as a discipline
historically tended to focus primarily on the role of healthcare pro-
fessionals in thepreventionof healthcare-associated (’nosocomial’)
infections. In 1997 the International Scientiﬁc Forum on Home
Hygiene (IFH) was formed with the mission to promote infection
prevention and control in the home setting and everyday life. Apart
from raising awareness of the important role of home hygiene in
preventing infectious diseases, the IFH has additionally aimed to
develop and promote hygiene and hygiene practices using sound
scientiﬁc principles. The IFH was, in many respects, an early pio-
neer in the recognition of the crucial role played by individuals
and their families in taking responsibility both independently and
togetherwith healthcare practitioners for infection prevention and
control (IPC) issues and personal health. More recently the role of
the patient and the family in IPC has been increasingly highlighted
bymany organizationsworldwide. IPC educationalmaterials, cam-
paigns and programs aimed at educating and empowering patients
and their families (one example is APIC’s ‘Infection Prevention and
YOU’ program aimed at “Spreading Knowledge. Preventing Infec-
tion”) arenoweasily available on theweb. This talkwill focus on the
roles of, and challenges experienced, by patients and their families
in safeguarding their health.
http://dx.doi.org/10.1016/j.ijid.2014.03.494
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Tracking resistance to antifungal drugs for
Candida spp
J. Coetzee
Johannesburg, South Africa
Fungal susceptibility testing has been coming of age in recent
years. Advances have included the establishment of species spe-
ciﬁc break point for different classes of antifungal agents, as well
as developments regarding the molecular detection of resistance
mutations. Experts previously believed the accurate speciation of
Candida isolates to be the most important determinant guiding
empirical choice of all antifungal agents. While this may still hold
true, resistance to antifungals have been emergingworldwide. This
is due to various factors, including the prophylactic use of antifun-
gal agents, the observation that under dosing of e.g. azoles such as
voriconazole can result in acquired resistance, and the increased
use of antifungals. The role of environmental factors in driving
resistance should also not be underestimated, as illustrated in the
recent discovery of azole resistant Aspergillus caused by the use
of azole based fungicides in agriculture. In comparing resistance
data from different regions in the world, it is important to note
both the date of the susceptibility testing as well as the interpre-
tive criteria use. Differences exist between the CLSI and EUCAST
breakpoints, and clinicians should be aware that the CLSI published
new break points in January 2013. These new break points have
had a signiﬁcant effect on the interpretive categorisation of cer-
tain drugs – e.g. lowering of voriconazole breakpoints for Candida
species. The methodology that was used to conduct the survey
should also be carefully noted, as the use of some of the com-
mercial antifungal susceptibility testing systemsmay be associated
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with a signiﬁcantmisclassiﬁcationof some species/antifungal com-
binations. In conclusion, historical data needs to be re-evaluated
according to the new breakpoints, in order to make meaningful
conclusions regarding the emergenceof resistance. Regular surveil-
lance studies tracking both the distribution aswell as susceptibility
patterns of Candida species to antifungal agents will provide guid-
ance to clinicians regarding empirical therapy.
http://dx.doi.org/10.1016/j.ijid.2014.03.495
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Invasive fungal infections in internal medicine
departments
F. Menichetti
Cisanello Hospital, Pisa, Italy
Candida spp. is an important cause of bloodstream infection
with high morbidity and mortality rate. The growing incidence
is usually related to the complexity of medical and surgical pro-
cedures in the critically-ill patient however, a recent three-year
survey conducted in Italy and Spain, clearly showed that the over-
all incidence was 1.55 cases per 1000 admissions, C. albicans was
the leading agent of infection (58,4%), and the majority of can-
didemia episodes were found in the internal medicine department
(49.6%), followed by the surgical ward, the ICU and the hemato-
oncology ward. The 30-days mortality rate was around 30%. The
higher rate of candidemia is therefore documented in the internal
medicine ward were non critically-ill patients are cared for. Apart
from lenght of hospital stay, broad-spectrum antibiotics and CVC,
risk factors for candidemiamaybe subtle and adelay in appropriate
diagnosis, especially when the blood culture results are negative,
mayrepresenta severe limiting factor in startinga timelyantifungal
therapy. One should take in account that non albicans Candida are
increasingly documented (C. parapsilosis 19.5%, C. tropicalis 9.3%,
C.glabrata 8.3%) and that around 5% of all tested isolates (n =955)
were resistant or susceptible dose dependent (SDD) to ﬂuconazole.
There are several reasons for considering an echinocandin in place
of ﬂuconazole for treating candidemia also in the non critically-
ill patients: broad spectrum of activity including C. krusei and C.
glabrata, fungicidal activity, anti-bioﬁlm activity, a reliable PK/PD
proﬁle, a good safety proﬁle, low rate of drug-drug interactions,
limited need for drug modiﬁcations in case of renal or liver fail-
ure, the burden of clinical evidence from clinical trials. However,
one should also consider the lower microbiological activity “in
vitro” against C. parapsilosis, the growingdocumentationof emerg-
ing resistance related to heavy use or abuse of echinocandins and
ﬁnally the cost. In summary, to be effective, antifungal therapy
should be timely (early start), appropriate (the right drug to the
right patient) and adequate (in terms of dose). Optimal antifungal
therapy should be offered to any patient with suspected or docu-
mented candidemia, including the non critcally-ill patient cared for
in the internal medicine departement.
http://dx.doi.org/10.1016/j.ijid.2014.03.496
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Early empiric therapy for invasive fungal
infection in the ICU
E. Mueller
EvK Herne, Herne, Germany
The risk of infection increases with the length of stay in the
intensive care unit (ICU). Invasive fungal infections (IFI) are now
responsible for a sizeable proportion of ICU infections. Candida spp.
are a particular problem in the ICU, where they are not only among
the most common pathogens responsible for blood stream infec-
tions (BSI), but also associated with an unexpectedly high rate of
mortality. Central venous catheters, total parenteral nutrition, and
increasingly, surgery, are common sources of Candida BSI. While
C. albicans remains the most common species implicated in can-
didemia, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, andother
non-albicans species are often responsible for infection, especially
among older patients (e.g., > 60 years). Risk scores and prediction
rules for Candida BSI are helpful, but not straightforward to apply.
There is also uncertainty around the appropriate length of therapy
for deep-seated Candida infections (e. g., intra-abdominal infec-
tions). Despite predictive, diagnostic, and treatment uncertainties,
correct assessment of patient risk factors for nosocomial Candida
infection is crucial to avoiding the poor outcomes associated with
delayed or inappropriate initial therapy. The reality is that many
ICU patients with Candida IFI are treated late or with ﬂuconazole
despite guidelines that an echinocandin be used as initial ther-
apy for critically ill patients. Furthermore, not all echinocandins
are equally effective, particularly when it comes to non-albicans
Candida infections. The problem of antifungal agents not being
interchangeable extends to treatment of invasive aspergillosis,
where selecting an agent such as voriconazole gives rise to con-
cerns about drug interactions and the need for therapeutic drug
monitoring. Given the increasing problem of candidemia in the ICU
and the shift to non-albicans species, especially in older patients,
early empiric therapy with an echinocandin is essential, as is con-
sideration of surgical co-intervention when urgent measures are
needed. Early empiric therapy with the appropriate echinocandin
and source control are the cornerstones of effective treatment for
Candida BSI.
http://dx.doi.org/10.1016/j.ijid.2014.03.497
